How Clinical Research Associates Can Stay Compliant With HIPAA & HITECH

Mohamad-Ali Salloum, PharmD • January 16, 2026

Share

  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
How Clinical Research Associates Can Stay Compliant With HIPAA & HITECH
Clinical Research · Privacy & Compliance

A practical guide for modern clinical research monitoring

Estimated read time: 6–7 minutes

TL;DR: If it identifies a patient, it’s PHI—and it must be protected. Use only secure, sponsor‑approved systems, access the minimum necessary, never export or transmit PHI in reports or emails, and escalate any suspected exposure immediately.

Clinical Research Associates (CRAs) play a frontline role in safeguarding the integrity of clinical trials. Beyond protocol adherence and data accuracy, CRAs must protect something equally important: patient privacy.

If you work on U.S.-based studies—or global studies that touch U.S. sites—two laws determine how patient information must be handled: HIPAA(Health Insurance Portability and Accountability Act) and HITECH(Health Information Technology for Economic and Clinical Health Act). Both set strict requirements for how Protected Health Information (PHI) is accessed, shared, stored, and secured.

Understanding PHI: What CRAs Need to Know

PHI is any patient information that can identify an individual. HIPAA lists 18 identifiers (e.g., name, address, DOB, MRN, full‑face photos). CRAs encounter PHI most during source data verification, EMR review, labs, clinic notes, and imaging.

Rule #1: If it identifies a patient, it’s PHI—and it must be protected.

Applying the Minimum Necessary Rule

HIPAA requires accessing only the information needed for the task at hand. For CRAs, that means:

  • Review only records relevant to enrolled study subjects
  • Avoid browsing unrelated chart sections
  • Do not request extra PHI that isn’t required for monitoring

Using the Right Technology—Securely

HITECH strengthened HIPAA’s digital security expectations. CRAs should follow strict technology practices.

Always use:

  • Sponsor‑approved EDC, CTMS, and eTMF systems
  • Encrypted email and secure portals for file exchange
  • Company‑issued devices with strong passwords and MFA
  • VPN when accessing systems remotely

Never use:

  • Personal email or messaging apps to view or share PHI
  • Screenshots or photos of PHI
  • Unencrypted USB drives
  • Personal cloud storage for study materials
If it’s not secure, it’s not compliant.

Remote & Onsite Monitoring: A Privacy Checklist

During onsite visits:

  • Never take PHI offsite
  • View PHI only in designated monitoring areas
  • Keep screens/documents out of public view
  • Make no handwritten notes with identifiers

During remote monitoring:

  • Use sponsor‑approved remote SDV platforms
  • Ensure screen shares exclude PHI unless explicitly permitted
  • Do not accept PHI via unencrypted email
  • Control your environment during screen share (close windows, prevent access)

Secure Your Workspace—Physical and Digital

Digital hygiene:

  • Lock your screen whenever you step away
  • Use strong, unique passwords and MFA
  • Avoid public Wi‑Fi—or use a VPN
  • Don’t store PHI locally on your device

Physical security:

  • Keep materials in zipped/locked bags; never leave docs in cars or public areas
  • Shred notes if they contain sensitive data
  • Do not carry paper PHI from a site

Reporting Incidents: When in Doubt, Escalate

HITECH expanded breach‑notification requirements. CRAs must promptly report:

  • Missing or stolen laptops/phones
  • PHI emailed to the wrong recipient or sent unencrypted
  • Viewing an incorrect subject’s chart
  • Any suspected unauthorized PHI exposure

CRAs don’t investigate— they escalate. Fast reporting protects patients and the study.

Compliance Is a Habit, Not a Task

The most compliant CRAs:

  • Understand what constitutes PHI
  • Use only secure, approved systems
  • Follow sponsor, CRO, and site SOPs
  • Keep data secure in all environments
  • Report incidents immediately
  • Avoid introducing PHI into study communications

Final Takeaway

For CRAs, HIPAA and HITECH compliance is about respecting the dignity and privacy of every study participant. Apply these principles consistently to protect patients, uphold data integrity, and strengthen the credibility of your work.



List of Services

    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    By Mohamad-Ali Salloum, PharmD May 23, 2026
    Why does this always happen?
    By Mohamad-Ali Salloum, PharmD May 21, 2026
    Discover the best ways to learn new skills
    By Mohamad-Ali Salloum, PharmD May 19, 2026
    Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
    By Mohamad-Ali Salloum, PharmD May 17, 2026
    References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
    By Mohamad-Ali Salloum, PharmD May 15, 2026
    References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285. 
    By Mohamad-Ali Salloum, PharmD May 13, 2026
    Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
    By Mohamad-Ali Salloum, PharmD May 11, 2026
    Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
    By Mohamad-Ali Salloum, PharmD May 9, 2026
    Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
    By Mohamad-Ali Salloum, PharmD May 7, 2026
    References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
    By Mohamad-Ali Salloum, PharmD May 4, 2026
    References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
    More Posts
    Share by: